Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.60 |
| ▸ | PYGM | P11217 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | TK2 | O00142 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465624 | 1.00 | TK1 (0.60) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| SCHEMBL465623 | 1.00 | TK1 (0.60) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| SCHEMBL3415528 | 1.00 | TK1 (0.60) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| SCHEMBL6314490 | 0.84 | LMNA (0.55) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL1129570 | 0.84 | LMNA (0.55) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL1130181 | 0.84 | LMNA (0.55) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL6753208 | 0.84 | SMN1; SMN2 (0.54) | TK1PYGMLMNASMN1; SMN2CYP1A2 | |
| SCHEMBL6760136 | 0.84 | LMNA (0.55) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL6752642 | 0.84 | LMNA (0.60) | TK1LMNASMN1; SMN2TSHRPMP22 | |
| SCHEMBL7701755 | 0.84 | LMNA (0.55) | TK1LMNATSHRBLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720840-B1 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | UNIV EMORY (US) | 2016-02-03 | — | — | EP | disclosed |
| US-8420354-B2 | Methods to manufacture 1,3-dioxolane nucleosides | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110130559-A1 | Methods to Manufacture 1,3-Dioxolane Nucleosides | GILEAD SCIENCES, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| EP-1534255-B1 | PROCESSES FOR PREPARING 1,3-DIOXOLANE NUCLEOSIDES | PHARMASSET INC (US) | 2011-01-19 | — | — | EP | disclosed |
| US-7785839-B2 | Methods to manufacture 1,3-dioxolane nucleosides | EMORY UNIVERSITY (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1720840-A4 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | UNIV EMORY (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-1720840-A2 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20060036092-A1 | Methods to manufacture 1,3-dioxolane nucleosides | SZNAIDMAN MARCOS | 2006-02-16 | — | — | US | disclosed |
| WO-2005074654-A2 | METHODS TO MANUFACTURE 1,3-DIOXOLANE NUCLEOSIDES | EMORY UNIVERSITY (US) | 2005-08-18 | — | — | WO | disclosed |
| US-6855821-B2 | Processes for preparing 1,3-dioxolane nucleosides | PHARMASSET, LTD. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040087806-A1 | Processes for preparing 1,3-dioxolane nucleosides | PHARMASSET, INC. | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087806-A1 | Processes for preparing 1,3-dioxolane nucleosides | NUDT1, PNP, DPYD | TK1 65/4885PYGM 1677/4885LMNA 788/4885 |
| US-20060036092-A1 | Methods to manufacture 1,3-dioxolane nucleosides | DCTD, AMPD1, DAD1 | TK1 265/4885PYGM 1817/4885LMNA 260/4885 |
| US-20110130559-A1 | Methods to Manufacture 1,3-Dioxolane Nucleosides | DCTD, AMPD1, DAD1 | TK1 254/4885PYGM 2104/4885LMNA 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.